Valuation: argenx SE

Capitalization 41.11B 47.85B 38.34B 35.63B 66.47B 4,321B 71.68B 441B 173B 2,065B 179B 176B 7,616B P/E ratio 2025 *
44.7x
P/E ratio 2026 * 27.9x
Enterprise value 38.09B 44.33B 35.52B 33B 61.58B 4,003B 66.4B 408B 160B 1,913B 166B 163B 7,055B EV / Sales 2025 *
10.6x
EV / Sales 2026 * 7.37x
Free-Float
99.23%
Yield 2025 *
0.02%
Yield 2026 * 0.04%
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.75%
1 week+1.96%
Current month-2.76%
1 month-7.46%
3 months+1.69%
6 months+45.06%
Current year-2.76%
More quotes
1 week 660.4
Extreme 660.4
711.6
1 month 660.4
Extreme 660.4
745.2
Current year 660.4
Extreme 660.4
728
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 9.23
Extreme 9.23
810
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 14/07/2008
Director of Finance/CFO 56 31/05/2021
Chief Tech/Sci/R&D Officer - 31/12/2014
Director TitleAgeSince
Director/Board Member 54 30/06/2014
Chairman 68 14/10/2008
Director/Board Member 76 12/05/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.75%+1.96%+8.23%+89.61% 48.01B
+6.00%+10.61%+96.03%+15.05% 41.97B
-2.38%-6.48%+137.52%+741.75% 35.77B
+4.90%+9.28%-5.76%-26.10% 25.64B
-0.74%+6.77%+33.50%-21.62% 20.81B
+5.85%+18.68%+131.28%-41.71% 19.92B
-1.35%-9.91%-7.51%+250.21% 13.14B
-4.36%+2.99%+114.78%+162.46% 14.9B
-1.68%+11.30%+190.69% - 14.63B
+0.05%+0.92%+24.87%+168.29% 11.86B
Average +0.95%+4.84%+72.36%+148.66% 24.67B
Weighted average by Cap. +1.81%+3.68%+69.75%+160.41%
See all sector performances

Financials

2025 *2026 *
Net sales 3.6B 4.18B 3.35B 3.12B 5.81B 378B 6.27B 38.55B 15.15B 181B 15.69B 15.37B 666B 4.97B 5.78B 4.63B 4.3B 8.03B 522B 8.66B 53.24B 20.92B 249B 21.67B 21.23B 920B
Net income 984M 1.15B 918M 853M 1.59B 103B 1.72B 10.55B 4.15B 49.44B 4.3B 4.21B 182B 1.74B 2.02B 1.62B 1.5B 2.81B 182B 3.03B 18.61B 7.31B 87.21B 7.58B 7.42B 322B
Net Debt -3.03B -3.52B -2.82B -2.62B -4.89B -318B -5.27B -32.43B -12.74B -152B -13.2B -12.93B -560B -4.53B -5.27B -4.23B -3.93B -7.33B -476B -7.9B -48.57B -19.09B -228B -19.77B -19.37B -839B
More financial data * Estimated data
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,599
More about the company
Date Price Change Volume
13/01/26 697.00 +3.75% 81,786
12/01/26 671.80 -3.14% 97,384
09/01/26 693.60 -0.49% 100,368
08/01/26 697.00 -0.88% 86,482
07/01/26 703.20 +2.51% 108,872

Real-time Euronext Bruxelles, January 13, 2026 at 04:55 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
697.00EUR
Average target price
824.20EUR
Spread / Average Target
+18.25%
Consensus

Quarterly revenue - Rate of surprise